Stéphan Walrand

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Roelf Valkema, Stanislas Pauwels, Larry K. Kvols et al. · PubMed · 2005 · 334 citations

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Raffaella Barone, Françoise Borson‐Chazot, Roelf Valkema et al. · PubMed · 2005 · 292 citations

86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

François Jamar, Raffaella Barone, Isabelle Mathieu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 239 citations

Urology, Renal Function, Medicine +10

Feasibility of 90Y TOF PET-based dosimetry in liver metastasis therapy using SIR-Spheres

Renaud Lhommel, Larry van Elmbt, Pierre Goffette et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2010 · 198 citations

Hepatology, Radiation Therapy, Medicine +9

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

Stanislas Pauwels, Raffaella Barone, Stéphan Walrand et al. · PubMed · 2005 · 165 citations

Pharmacotherapy, Molecular Pharmacology, Practical Dosimetry +18